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Dear Editor
Re: Pavelka K, Gatterova J, Gallerova V, Urbanova Z,
Sedlackova M, Altman R. A 5-year randomized con-
trolled double-blind study of glycosaminoglycan
polysulfuric acid complex (Rumalon) as a structure-
modifying therapy in osteoarthritis of the hip and knee.
Osteoarthritis Cart 2000;8:335–342.
First of all, we wish to congratulate the authors for publish-
ing a trial with negative results, a too rare initiative. This
study is not the first negative trial with regard to the
structure modifying effect of Rumalon. If the authors had
referred not only to my editorial (which should have carried
its correct English name)1, but preferably to my main study
on chrondrometry2, they would have found in the body of
the text details of the first randomized double blind study of
Rumalon vs placebo over a 3-year period: joint space loss
was 0.72±0.71 and 0.60±0.69 respectively, i.e. a non-
significant difference, a result first published as an abstract
in 19923. This study was conducted by using one of the
methods tested in our department. All successive methods
and improvements were studied in cooperation with
Christian Cadet, following his university thesis in 1984,
entitled ‘Preciseness of the measurement of the osteo-
arthritic hip joint space and of its change over time. Does it
represent a valuable criterion of the disease’s course?’ A
few years later, we performed a similar study on the OA
knee structural change.
Last but not least, Christian Cadet participated in
Pavelka et al.’s trial by going to Prague as one of the
measurers for all the numerous initial and final radiographs
they had to deal with. Moreover, he established the
Kellgren–Lawrence OA stages on radiographs (incidentally,
the proportion of stages 0 and 1, i.e. doubtful, is very high,
close to 50% for the hips in this study . . .). We were
surprised that not only is his name missing as a co-author
of this paper, but also he is not even mentioned amongst
those deserving acknowledgements. We hope that this is
only an oversight and that the authors will find it fitting to
make up for this memory lapse.
M. Lequesne, MD
Department of Rheumatology
Leopold Bellan Hospital
19 rue Vercinge´torix
75014 Paris
France
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Response to Letter to the Editor
The authors would like to thank M. Lequesne for his
comments. Dr Lequesne helped in the design and conduct
of the study as an adviser.
Although we would have liked to recognize Dr
Lequesne’s study ‘Joint space narrowing in primary
osteoarthritis of the hip. Results of a three year controlled
trial’. The study was published only in abstract and an
adequate review of the study was not possible.
Dr Cadet did indeed perform the measurement of JSW.
However, he was under contract with the sponsor. There
was no collaboration involved and he did not otherwise
contribute to the design, conduct, interpretation or
publication of the trial.
It is appreciated that he could have been mentioned in
the acknowledgments. We thank Dr Lequesne for bringing
this to our attention and will write a personal letter to
Dr Cadet thanking him for his contribution.
Professor Karel Pavelka, M.D.
Institute of Rheumatology Prague
Na slupi 4, 128 50 Prague 2
Czech Republic

